The Oxford Science Park

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

The Oxford Science Park team runs for children’s hospital

31 Mar 2026

A team of 30 runners from across The Oxford Science Park came together last month to take part in the annual OX5 Run at Blenheim Palace, raising an impressive £2,851 for the Oxford Children’s Hospital and children’s services within the Oxford University Hospitals NHS Foundation Trust. Representing a wide range of organisations based at the Park, participants included colleagues from Sitryx, Bond Williams, Enara Bio, Orthoson, the Ellison... Read more

Constantin Coussios appointed Pro-Vice-Chancellor for Innovation

30 Mar 2026

The Oxford Science Park (TOSP) warmly congratulates Professor Constantin Coussios on his appointment as Pro-Vice-Chancellor for Innovation at the University of Oxford, a role he will take up at the end of April 2026. A pioneer in biomedical engineering and a driving force behind some of Oxford’s most successful spinouts, Professor Coussios has long been embedded in the innovation community that thrives at the Park. His appointment marks a... Read more

Evox Therapeutics enters partnership to evaluate new gene editing technology for Rett Syndrome

27 Feb 2026

Evox Therapeutics, a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality, has announced it is initiating a collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the company’s ExoEdit® exosome-based delivery platform to enable the development of a gene editing treatment for Rett syndrome. Rett syndrome is a... Read more

Boehringer Ingelheim licenses novel oral therapeutics program from Sitryx Therapeutics

27 Feb 2026

Boehringer has acquired an exclusive license for a preclinical, small molecule program from Sitryx, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, based at The Oxford Science Park. The deal includes upfront and milestone payments to Sitryx totaling over US $500 million, plus tiered royalties. The program offers a novel, oral, potentially... Read more

CyanoCapture to build world's first robotic GMP facility for oral peptides with Persist AI

25 Feb 2026

CyanoCapture, the innovator in cyanobacteria-based oral drug delivery, and Persist AI, the leader in AI-driven robotic pharmaceutical formulation, have announced a strategic collaboration to jointly build a next-generation GMP manufacturing facility in the San Francisco Bay Area. The facility, expected to be operational later this year, will be the first of its kind to combine cyanobacteria culture and processing with robotic automation for... Read more

News